Changes in Hong Kong stocks | Yaojie Ankang-B (02617) rose by nearly 14% and recently announced the publication of positive clinical results of tengotinib in the “Lancet” sub-magazine

The Zhitong Finance App learned that Yaojie Ankang-B (02617) rose by nearly 14%. As of press release, it had risen 13.85% to HK$166.1, with a turnover of HK$112 million.

According to the news, according to Yaojie Ankang's WeChat account, recently, the company announced that the results of phase 2 exploratory clinical trials of cholangiocarcinoma carried out in the US with the core product tengotinib were published in “The Lancet, Gastroenterology, and Hepatology” (Impact Factor 38.6). To this end, researchers at the University of Texas MD Anderson Cancer Center commented: “We are looking for next-generation FGFR2 inhibitors against drug resistance. As a next-generation FGFR inhibitor, tengotinib targets FGFR with a unique mechanism. In this phase 2 study, tengotinib showed long-lasting remission and increased survival in patients with cholangiocarcinoma. This impressive data supports the launch of the Phase 3 registration trial.”

According to reports, tengotinib is an innovative multi-target small molecule kinase inhibitor developed independently and in the registered clinical stage. It exerts an anti-tumor effect by targeting tumor cells and improving the tumor microenvironment. Currently, tengotinib has carried out a number of clinical trials in China and the US for solid tumors such as cholangiocarcinoma, prostate cancer, and breast cancer, and has obtained “orphan drug certification” (ODD) and “fast track qualification certification” from the US FDA for the treatment of cholangiocarcinoma. China's NMPA approved inclusion in the list of breakthrough treatment types and priority review varieties, and orphan drug certification (ODD) granted by the European EMA for treating biliary tract cancer.